The Technical Analyst
Select Language :
Apellis Pharmaceuticals [APLS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Apellis Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Apellis Pharmaceuticals is listed at the  Exchange

-0.86% $58.49

America/New_York / 27 mar 2024 @ 16:00


Apellis Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 7 052.84 mill
EPS: -4.45
P/E: -13.14
Earnings Date: May 01, 2024
SharesOutstanding: 120.58 mill
Avg Daily Volume: 1.584 mill
RATING 2024-03-27
B-
Sell
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -13.14 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-2.24x
Company: PE -13.14 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-36.31
(-162.08%) $-94.80
Date: 2024-03-28
Expected Trading Range (DAY)

$ 55.11 - 61.88

( +/- 5.79%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-19 Dunlop A. Sinclair Sell 18 681 Common Stock
2024-03-18 Delong Mark Jeffrey Sell 9 913 Common Stock
2024-03-15 Chopas James George Sell 184 Common Stock
2024-03-13 Nicholson Nur Sell 7 768 Common Stock
2024-03-13 Nicholson Nur Sell 3 452 Common Stock
INSIDER POWER
9.56
Last 100 transactions
Buy: 1 004 484 | Sell: 797 634

Forecast: 16:00 - $58.47

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $58.47
Forecast 2: 16:00 - $58.47
Forecast 3: 16:00 - $58.47
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $58.49 (-0.86% )
Volume 1.023 mill
Avg. Vol. 1.584 mill
% of Avg. Vol 64.61 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Apellis Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Apellis Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Apellis Pharmaceuticals Inc

Last 10 Buy & Sell Signals For APLS

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$67.82N/AActive
Profile picture for
            Apellis Pharmaceuticals Inc

APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Last 10 Buy Signals

Date Signal @
ZRXUSDMar 28 - 06:27$1.086
C98USDMar 28 - 06:270.399
WETHUSDMar 28 - 06:243 580.01
MSOLUSDMar 28 - 06:23219.13
ORDIUSDMar 28 - 06:2462.42
ERNUSDMar 28 - 06:24$6.29
AGIXUSDMar 28 - 06:251.370
ATOMUSDMar 28 - 06:25$12.47
SNXUSDMar 28 - 06:24$4.87
ALCXUSDMar 28 - 06:24$33.62

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.